StockNews.com Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)

StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Trading Up 2.4 %

Shares of NASDAQ TENX opened at $3.40 on Wednesday. The company’s 50-day simple moving average is $3.33 and its 200-day simple moving average is $4.99. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Equities analysts expect that Tenax Therapeutics will post -7.96 EPS for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.